1-(Pyrimidin-4-yl)ethane-1-thiol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(Pyrimidin-4-yl)ethane-1-thiol
• 英文别名: 1-pyrimidin-4-ylethanethiol
• 化学式: C₆H₈N₂S
• 分子量: 140.21
• InChiKey: ZWVSUUJYIVLJGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
  申请人：ESSA Pharma, Inc.

  公开号：US20200123117A1

  公开（公告）日：2020-04-23

  The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

  本发明涉及公式（I）-（VI）和/或（A）-（H-I）的化合物，或其任何亚属，或药学上可接受的盐、互变异构体或立体异构体。本公开的化合物在调节雄激素受体活性和治疗包括前列腺癌在内的癌症方面具有用途。
• [EN] ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR D'ARYLE-HYDROCARBONE (AHR) ET LEURS UTILISATIONS
  申请人：IKENA ONCOLOGY INC

  公开号：WO2022133480A1

  公开（公告）日：2022-06-23

  The present invention provides AHR agonists, composites thereof, and methods of using the same.

  本发明提供AHR激动剂、其复合物以及使用方法。
• ACLY INHIBITORS AND USES THEREOF
  申请人：Nimbus Artemis, Inc.

  公开号：US20200157076A1

  公开（公告）日：2020-05-21

  The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.
• MODULATORS OF THE INTEGRATED STRESS PATHWAY
  申请人：Calico Life Sciences LLC

  公开号：US20220106281A1

  公开（公告）日：2022-04-07

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
• PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF
  申请人：ESSA Pharma, Inc.

  公开号：US20220202780A1

  公开（公告）日：2022-06-30

  The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor modulator or an inhibitor and a second therapeutically active agent, such as an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer.